Patrizio Armeni
Associate Professor of Practice di Government, Health and Not for Profit
OSFAR
Pharmaceutical Observatory
The Pharmaceutical Observatory (OSFAR) of CERGAS-SDA Bocconi was born in 1997. At present OSFAR is supported by eight major multinational pharmaceutical companies (Astrazeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD Italia, Novartis, Pfizer, Sanofi, Takeda) with an annual unrestricted grant.
The research of OSFAR is focused on pharmaceutical market trend, pharmaceutical policy, policy impact analysis and patients access to medicines.
Since 1997, OSFAR, the Pharmaceutical Observatory of CERGAS SDA Bocconi collects, systematizes and analyzes:
- qualitative data on public policies and the management systems of the pharmaceutical assistance, in particular those of licensed pharmacies
- quantitative data on the trend of public and private pharmaceutical expenditure at international, national and regional levels
- the effects of pharmaceutical assistance policies and management systems on the expenditure trend.
The data collected are then used by OSFAR to prepare the Report: an analysis of public and private pharmaceutical expenditure at an international, national and regional level.
Research Team
Francesco Costa
Coordinator. Associate Professor of Practice of Government, Health & Not for Profit
Claudio Jommi
Professor of Practice in Health Policy
Francesco Malandrini
Associate Professor of Practice of Government, Health & Not for Profit
Monica Otto
scientific supervisor. Lecturer at the Department of Social and Political Sciences
Partner
Publications
The main activity of OSFAR, the Pharmaceutical Observatory of SDA Bocconi is the annual publication of the report, which contains:
- a quantitative analysis of macro-variables relating to the economic and healthcare sector systems (national and international)
- an analysis of public and private pharmaceutical expenditure and consumption at national and regional level
- forecasts of public and private pharmaceutical expenditure and consumption for the current and following year;
- an analysis of the regulation policies for the pharmaceutical sector and their effects on the expenditure trend.